A detailed history of Morgan Stanley transactions in Pep Gen Inc. stock. As of the latest transaction made, Morgan Stanley holds 58,856 shares of PEPG stock, worth $242,486. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58,856
Previous 27,026 117.78%
Holding current value
$242,486
Previous $431,000 16.71%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.75 - $18.55 $246,682 - $590,446
31,830 Added 117.78%
58,856 $503,000
Q2 2024

Oct 17, 2024

SELL
$10.54 - $18.14 $15,346 - $26,411
-1,456 Reduced 5.11%
27,026 $431,000
Q2 2024

Aug 14, 2024

SELL
$10.54 - $18.14 $15,346 - $26,411
-1,456 Reduced 5.11%
27,026 $431,000
Q1 2024

Oct 17, 2024

BUY
$6.63 - $17.3 $9,653 - $25,188
1,456 Added 5.39%
28,482 $418,000
Q1 2024

Aug 16, 2024

SELL
$6.63 - $17.3 $49,294 - $128,625
-7,435 Reduced 20.7%
28,482 $418,000
Q1 2024

May 15, 2024

SELL
$6.63 - $17.3 $49,294 - $128,625
-7,435 Reduced 20.7%
28,482 $418,000
Q4 2023

Aug 16, 2024

BUY
$3.86 - $7.96 $34,319 - $70,772
8,891 Added 32.9%
35,917 $244,000
Q4 2023

Feb 13, 2024

BUY
$3.86 - $7.96 $100,302 - $206,840
25,985 Added 261.63%
35,917 $244,000
Q3 2023

Nov 15, 2023

SELL
$5.0 - $9.09 $23,320 - $42,395
-4,664 Reduced 31.95%
9,932 $50,000
Q2 2023

Aug 14, 2023

BUY
$8.94 - $16.39 $13,713 - $25,142
1,534 Added 11.74%
14,596 $130,000
Q1 2023

May 15, 2023

BUY
$11.44 - $17.7 $78,855 - $122,006
6,893 Added 111.74%
13,062 $159,000
Q4 2022

Feb 14, 2023

BUY
$9.31 - $16.57 $45,274 - $80,579
4,863 Added 372.36%
6,169 $82,000
Q3 2022

Nov 14, 2022

BUY
$4.86 - $12.75 $233 - $612
48 Added 3.82%
1,306 $12,000
Q2 2022

Aug 15, 2022

BUY
$9.0 - $12.89 $11,322 - $16,215
1,258 New
1,258 $13,000

Others Institutions Holding PEPG

About PepGen Inc.


  • Ticker PEPG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,631,900
  • Market Cap $97.4M
  • Description
  • PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is a...
More about PEPG
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.